Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Vomiting

Vomiting

69

Pipeline Programs↗

57

Active Trials↗

47

Companies Involved↗

Vomiting is a moderately active landscape with 69 programs across 47 companies. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

56/100

Mech. Concentration

30/100

Completion Rate

88/100

Attrition Rate

9/100

Pipeline

Programs by Phase

Preclinical61

Divalproex Sodium

Teva

Fosaprepitant

Merck & Co.

Ondansetron Oral Membrane

Shanghai Children's Medical Center

Granisetron Hydrochloride

Conrado Roberto Hoffmann Filho

Palonosetron Only

Yonsei University

Phase 1

No programs

Phase 2

No programs

Phase 38

Nab-Paclitaxel

Bristol-Myers Squibb

Gemcitabine

Johnson & Johnson

Thalidomide

Bristol-Myers Squibb

Medroxyprogesterone Acetate

Eli Lilly

Tradipitant

Vanda Pharmaceuticals

Approved

No programs

Analysis

Trial Status

452

clinical trials

Completed290 · 64%

Unknown status63 · 14%

Recruiting31 · 7%

Terminated31 · 7%

Not yet recruiting22 · 5%

Withdrawn10 · 2%

Other5 · 1%

Clinical Trials

Trial Activity

452 trials

A Multicentre, Multinational, Pharmacokinetic, Safety, and Efficacy Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC). A 2-part Study With Phase 2, Open-label, Randomised, Single-dose IV NEPA vs Fosaprepitant/Ondansetron in Single-day HEC and Repeated-dose IV NEPA in Multi-day HEC (Part I, Single Cycle) and With Phase 3, Double-blind, Randomised, Repeated-dose IV NEPA vs Fosaprepitant/Ondansetron in Multi-day HEC (Part II, Repeated Cycles)

Recruiting·HHelsinn Healthcare SA·Phase 2·NCT06904235·95 enrolled

Early Postoperative Pain and Related Outcomes After Cardiac Surgery: A Retrospective Cohort Study

Recruiting·Antalya Training and Research Hospital·N/A·NCT07804732·99 enrolled

Time-to-first-rescue Antiemetic With Ondansetron Plus Metoclopramide Versus Dexamethasone Plus Metoclopramide for PONV Prophylaxis in Laparoscopic Cholecystectomy: a Randomized, Triple-Blind, Superiority Trial

Recruiting·Faisalabad Medical University·Approved·NCT07638527·264 enrolled

Pain and Nausea in the Post-Anaesthesia Care Unit After Bariatric Surgery: A Registry Study Linking the Swedish Perioperative Register (SPOR) and the Scandinavian Obesity Surgery Registry (SOReg)

Recruiting·UUmeå University·N/A·NCT07797374·30,000 enrolled

Risk of Early Postoperative Nausea and Vomiting (PONV) - a Study With Data From the Swedish Perioperative Register (SPOR).

Recruiting·—·N/A·NCT04433676·1,500,000 enrolled

Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial

Recruiting·—·Preclinical·NCT07768124·60 enrolled

Cortical Excitability in Cyclic Vomiting Syndrome

Recruiting·UUniversity of Pittsburgh·Preclinical·NCT05256160·110 enrolled

A Multicenter, Exploratory Clinical Study of the Efficacy and Safety of Phentolamine and Palonosetron for the Prevention of Nausea and Vomiting Associated With Recom-Trastuzumab Therapy

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07726433·56 enrolled

TMS Neuromodulation of Brain-to-Stomach Circuits in Chronic Nausea

Recruiting·—·Preclinical·NCT07276035·219 enrolled

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan in Breast Cancer Palliative Therapy

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07716189·74 enrolled

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Combined With Cyclophosphamide in Breast Cancer Adjuvant Chemotherapy

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07716176·74 enrolled

Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound in Pancreatic Cancer Treatment

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07716228·74 enrolled

Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy

Recruiting·—·Phase 4·NCT07217600·60 enrolled

Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy

Recruiting·UUmeå University·Phase 4·NCT03783182·100 enrolled

Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan

Recruiting·—·Phase 3·NCT06588413·172 enrolled

Page 1 of 31

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)